Rigel Says Most Of Vepinu's $6.6 Million Launch Was Real Demand, Not Stocking

The cancer drug's first sales covered about six weeks, and the CFO said guidance on it will wait until after the first of the year.

Share
Rigel Says Most Of Vepinu's $6.6 Million Launch Was Real Demand, Not Stocking

Rigel Pharmaceuticals, which develops and sells drugs for blood disorders and cancer, said on its third-quarter earnings call Thursday that the bulk of Vepinu's $6.6 million in launch sales came from patient demand, not inventory stocking. Chief Financial Officer Dean Schorno said the company will pick a time for Vepinu guidance after the first of the year.

Demand, not stocking

Asked by an analyst how much of the $6.6 million was initial channel stocking, Chief Commercial Officer Dave Santos said, "I can say very firmly that the bulk of our sales were demand-related as opposed to inventory stocking." The sales reflect about six weeks of availability; Vepinu became available in the U.S. on August 13, CEO Raul Rodriguez said.

Santos said Vepinu shipped to more than 100 patients and clinics in that span, and that most patients who started in August had received a first refill by quarter end. Prior-authorization approval was estimated at 88%, and the median time to fill was four days.

On October trends, Santos would not give specifics. "You'll have to wait until next year to hear those. But we expect it to grow," he said. He added that the company will not keep offering this level of launch detail.

Community oncology leads

Santos said community oncology makes up about 70% to 80% of Vepinu business, counting both prescribers and ordering accounts. He called that a little different from what you would expect for a new cancer drug.

Rodriguez said the drug could become Rigel's largest sales contributor, and that net product sales have grown at a compound rate of about 35% a year since 2022. Vepinu is Rigel's fourth commercial product, alongside Tavalisse, Rezlidhia and Gavreto.

Quarter and guidance

Net product sales were $72.3 million, up 13% year over year, the company's highest ever, Rodriguez said. Tavalisse brought in $46 million (up 3%), Rezlidhia $9.9 million (up 20%) and Gavreto $9.8 million (down 11%). Total revenue was $80.9 million, and net income was $13.2 million.

Rigel now expects total 2026 revenue of about $290 million to $295 million, narrowed from $285 million to $295 million. That includes $255 million to $260 million of net product sales excluding Vepinu, from $255 million to $265 million, and about $35 million of contract revenue, up from $30 million. Schorno said that once the company has "enough clarity of the business," it will set Vepinu guidance. Rigel still expects positive net income for the year. Its market value was about $958 million.

Rigel is scheduled to present updated data on its R289 drug candidate in lower-risk myelodysplastic syndrome in an oral session at the ASH meeting on Saturday, December 12.

Sources